Bone Biologics (OTC:BBLG) Trading Down 11.7% – Should You Sell?

Bone Biologics Co. (OTC:BBLG)’s stock price dropped 11.7% during mid-day trading on Wednesday . The stock traded as low as $4.85 and last traded at $4.91. Approximately 59,228 shares were traded during mid-day trading, an increase of 84% from the average daily volume of 32,149 shares. The stock had previously closed at $5.56.

Bone Biologics Stock Down 11.7%

The firm has a market cap of $16.06 million, a price-to-earnings ratio of -0.10 and a beta of 0.75. The business has a 50 day moving average of $4.49 and a 200 day moving average of $5.49.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.